Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.

Slides:



Advertisements
Similar presentations
NUR 141: SKILL 28-3: CHANGING INTRAVENOUS SOLUTIONS
Advertisements

Regulatory Pathway for Platform Technologies
Part 15 Public Hearing FDA Regulation of Combination Products November 25, 2002 Rockville, MD Michael Gross, Ph.D., RAC Vice-President Worldwide Compliance.
Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
Carolyn McCune, RN, MSN, CRNP Teresa Peck RN, BSN.
Parenteral Therapy Intravenous Therapy (IV) involves injecting a medication directly into the blood via venous access devices IV products must be sterile.
NUR 141: SKILL 28-4: CHANGING INFUSION TUBING
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
IAEA International Atomic Energy Agency Responsibility for Radiation Safety Day 8 – Lecture 4.
510k Submission Overview Myraqa, Inc. August 22, 2012.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.
Preparing and Administering Medications
Fundamental Nursing Chapter 35 Intravenous Medications
Cross-Labeling: Legal and Regulatory Issues David M. Fox Hogan & Hartson LLP th Street, NW Washington, DC
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Office of Combination Products: Current Initiatives
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.
What Makes a Good Medical Device Adverse Event Report?
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
FDA’s Role in Encouraging Innovation in Combination Products Danelle R. Miller, Esq. Regulatory Counsel, Roche Diagnostics For The Combination Products.
Copyright ©2012 by Pearson Education, Inc. All rights reserved. Emergency Care, Twelfth Edition Limmer O’Keefe Dickinson Introduction to Emergency Medical.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 4 Drug Labels and Packaging.
Prime Responsibility for Radiation Safety
1 Cross Labeling Combination Products Bradley Merrill Thompson, MBA, JD, RAC Epstein Becker & Green PC.
Legal Considerations in Cross Labeling Policy Nancy Stade Assoc. Chief Counsel, Devices FDA/DIA Combination Products and Mutually Conforming Labeling Workshop.
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 35 Intravenous Medications.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
NANS I3 Technology Gaps in Intrathecal Drug Delivery Systems
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
Regulatory and Legal Challenges for Developers of Drug Delivery Devices Public Workshop: Innovative Systems for Delivery of Drugs.
FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
The Pharmacy Technician
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
10: General Pharmacology
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
COPYRIGHT ALL RIGHTS RESERVED. LEGAL DISCLOSURE. November 25, 2002 PRESENTATION TO: Public Hearing: FDA Regulation of Combination Products November.
Calculation of Basic IV Drip Rates
Emergency Care CHAPTER Copyright © 2016, 2012, 2009 by Pearson Education, Inc. All Rights Reserved Emergency Care, 13e Daniel Limmer | Michael F. O'Keefe.
75 years of excellence Combination Products NEMA’s Comments for the Office of Combination Products Public Hearing Terry Sweeney, Philips Medical Systems.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Clinical Trials.
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
Chapter 31 Medication Administration. Injections: Intravenous  Three methods:  As mixtures within large volumes of IV fluids  By injection of a bolus.
Guidance for review of studies involving HCT/Ps and IND Basics
Regulatory Considerations for Coronary Drug Coated Balloons (DCBs)
FDA Perspective on Cardiovascular Device Development
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Fundamental Nursing Chapter 35 Intravenous Medications
Chapter 35 Intravenous Medications
SAFE INJECTION PRACTICES
Chapter 3 Administration of Aerosolized Agents
Michael Gross, Ph.D., RAC Vice-President Worldwide Compliance
Fundamental Nursing Chapter 35 Intravenous Medications
Regulatory Perspective of the Use of EHRs in RCTs
Chapter 35: Intravenous Medications
Parenteral Dosages Chapter 12
Presentation transcript:

Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices and Radiological Health

FDA Mission Stated most simply, FDA's mission is to promote and protect the public health by helping safe and effective products reach the market in a timely way, To monitor products for continued safety after they are in use, and To help the public get the accurate, science-based information needed to improve health.

The Balancing Act Promotion of public health - expedite approval of innovative products that have potential for positive impact on public health Protection of public health – ensure that all medical products are adequately tested for safety, that labeling provides adequate directions for safe use

General Purpose Drug Delivery Systems CDRH has a long history of clearing unfilled general purpose drug delivery systems through 510(k) Examples: External infusion pumps 21 CFR “An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner. The device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically. The device may also operate using a constant force to propel the fluid through a narrow tube which determines the flow rate.” I.V. Administration Set 21 CFR “An intravascular administration set is a device used to administer fluids from a container to a patient`s vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.”

General Purpose Drug Delivery Systems (cont.) Nebulizer 21 CFR “A nebulizer is a device intended to spray liquids in aerosol form into gases that are delivered directly to the patient for breathing. Heated, ultrasonic, gas, venturi, and refillable nebulizers are included in this generic type of device.” Catheter 21 CFR “An intravascular catheter is a device that consists of a slender tube and any necessary connecting fittings and that is inserted into the patient`s vascular system for short term use (less than 30 days) to sample blood, monitor blood pressure, or administer fluids intravenously. The device may be constructed of metal, rubber, plastic, or a combination of these materials.”

General Purpose Drug Delivery Devices In general, mutually conforming labeling not an issue Not pre-filled with drug No indications or claims for delivery of a specific drug or biologic There are one or many drugs already approved by FDA that can be delivered by these devices by this route of administration Submitter of 510(k) needs to show adequate safety and performance as a tool for delivery of drugs or biologics, i.e., devices are substantially equivalent to a legally marketed predicate Submitter of 510(k) does not need to show that the combination of drug and device is safe and effective

Specific drug delivery systems CDER lead Pre-filled with drug Pre-filled syringes Metered dose inhalers Photodynamic therapy devices Drug/device only effective in combination Implanted infusion pumps Device design/use may affect drug stability

Drug Delivery systems: When do questions arise? Proposed indication for use for device would necessitate a change in the route of administration for approved drugs Devices indicated for infusion of therapeutic drugs into the neurovasculature Devices indicated for targeted delivery of chemotherapeutic agents

Drug Delivery systems: When do questions arise? Devices intended for enhancement of drug effects – combined use may have a different safety/efficacy profile Devices used to prepare skin prior to administration of lidocaine Use of device as labeled may necessitate a change in dosing of approved drugs Breath actuated nebulizers Patient controlled infusion pumps for pain medication

Mutually conforming labeling: helping to ensure patient safety By (sometimes) requiring that drug labels be changed to reflect changes to indication, route of administration or dosing that are facilitated by a new device, FDA helps ensure patient safety: Adequate information is provided to users on both the drug and device labels Postmarket safety information is collected on the combined use, labels updated accordingly New uses are thoroughly evaluated by FDA experts in both centers according to their respective regulatory authorities

Mutually conforming labeling: manufacturing concerns In the absence of mutually conforming labels (and an agreement between drug and device companies), changes to drug formulations or changes to device design are not communicated Example: changes to endotoxin level of IV drug, impact on device for intrathecal drug delivery Example: changes to laser output of photodynamic therapy device

Summary FDA regulations allow flexibility to clear devices as general purpose drug delivery systems when appropriate Questions arise when the device use requires an unapproved drug use (indication, route of administration or dose) Mutually conforming labeling helps to ensure safe and effective use of the combination product and helps FDA achieve our mission